IP Library Patent Application 18065223
Patent Application
App. No. 18/065,223

ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/065,223
Abstract

Provided herein are HLA-PEPTIDE targets and antigen binding proteins that bind HLA-PEPTIDE targets. Also disclosed are methods for identifying the HLA-PEPTIDE targets as well as identifying one or more antigen binding proteins that bind a give n HLA-PEPTIDE target.

Claims (44)

1 - 96 . (canceled)

97 . An isolated HLA-PEPTIDE target, wherein the HLA-PEPTIDE target comprises an HLA-restricted peptide complexed with an HLA Class I molecule, wherein the HLA-restricted peptide is located in the peptide binding groove of an α1/α2 heterodimer portion of the HLA Class I molecule, and wherein the HLA-PEPTIDE target is selected from Table A, with the proviso that the isolated HLA-PEPTIDE target is not any one of Target nos. 6364-6369, 6386-6389, 6500, 6521-6524, or 6578 and is not an HLA-PEPTIDE target found in Table B or Table C.

98 . The isolated HLA-PEPTIDE target of claim 97 , wherein

a. the HLA Class I molecule is HLA subtype A*02:01 and the HLA-restricted peptide comprises the sequence LLASSILCA,

b. the HLA Class I molecule is HLA subtype A*01:01 and the HLA-restricted peptide comprises the sequence EVDPIGHLY,

c. the HLA Class I molecule is HLA subtype B*44:02 and the HLA-restricted peptide comprises the sequence GEMSSNSTAL,

d. the HLA Class I molecule is HLA subtype A*02:01 and the HLA-restricted peptide comprises the sequence GVYDGEEHSV,

e. the HLA Class I molecule is HLA subtype *01:01 and the HLA-restricted peptide comprises the sequence EVDPIGHVY, or

f. the HLA Class I molecule is HLA subtype HLA-A*01:01 and the HLA-restricted peptide comprises the sequence NTDNNLAVY.

99 . The isolated HLA-PEPTIDE target of claim 98 , comprising HLA subtype A*02:01 complexed with a restricted peptide consisting of or consisting essentially of the sequence LLASSILCA.

100 . The isolated HLA-PEPTIDE target of claim 97 , wherein the HLA-restricted peptide is between about 5-15 amino acids in length or between about 8-12 amino acids in length.

101 . (canceled)

102 . (canceled)

103 . The isolated HLA-PEPTIDE target of claim 97 , wherein the association of the HLA subtype with the restricted peptide stabilizes non-covalent association of the β2-microglobin subunit of the HLA subtype with the α-subunit of the HLA subtype.

104 . The isolated HLA-PEPTIDE target of claim 103 , wherein the stabilized association of the β2-microglobin subunit of the HLA subtype with the α-subunit of the HLA subtype is demonstrated by conditional peptide exchange.

105 . The isolated HLA-PEPTIDE target of claim 97 , further comprising an affinity tag.

106 - 110 . (canceled)

111 . A composition comprising the HLA-PEPTIDE target of claim 97 attached to a solid support.

112 . The composition of claim 111 , wherein the solid support comprises a bead, well, membrane, tube, column, plate, sepharose, magnetic bead, or chip.

113 . The composition of claim 111 , wherein the HLA-PEPTIDE target comprises a first member of an affinity binding pair and the solid support comprises a second member of the affinity binding pair.

114 . (canceled)

115 . (canceled)

116 . A reaction mixture comprising

a. the isolated HLA-PEPTIDE target of claim 97 ; and

b. a plurality of T-cells isolated from a human subject.

117 . (canceled)

118 . (canceled)

119 . A kit for expressing a stable HLA-PEPTIDE target, comprising a first construct comprising a first nucleic acid sequence encoding an HLA-restricted peptide as defined in claim 97 operably linked to a promoter; and instructions for use in expressing the stable HLA-PEPTIDE complex.

120 - 150 . (canceled)

151 . A composition comprising (i) at least one HLA-PEPTIDE target of claim 97 and (ii) an adjuvant or a pharmaceutically acceptable excipient.

152 - 162 . (canceled)

163 . A method of identifying an antigen binding protein, comprising obtaining at least one HLA-PEPTIDE target listed in Table A; administering the HLA-PEPTIDE target to a subject, optionally in combination with an adjuvant; and isolating the antigen binding protein from the subject.

164 . The method of claim 163 , wherein isolating the antigen binding protein comprises screening the serum of the subject to identify the antigen binding protein.

165 . The method of claim 163 , further comprising contacting the antigen binding protein with one or more peptide-HLA complexes that are distinct from the HLA-PEPTIDE target to determine if the antigen binding protein selectively binds to the HLA-PEPTIDE target, optionally wherein selectivity is determined by measuring binding affinity of the antigen binding protein to soluble target HLA-PEPTIDE complexes versus soluble HLA-PEPTIDE complexes that are distinct from target complexes, optionally wherein selectivity is determined by measuring binding affinity of the antigen binding protein to target HLA-PEPTIDE complexes expressed on the surface of one or more cells versus HLA-PEPTIDE complexes that are distinct from target complexes expressed on the surface of one or more cells.

166 . (canceled)

167 . The method of claim 163 , wherein isolating the antigen binding protein comprises isolating a B cell from the subject that expresses the antigen binding protein and optionally directly cloning sequences encoding the antigen binding protein from the isolated B cell.

168 . The method of claim 167 , further comprising (i) creating a hybridoma using the B cell, (ii) cloning CDRs from the B cell, (iii) immortalizing the B cell, or (iv) creating a library that comprises the antigen binding protein of the B cell.

169 - 172 . (canceled)

173 . A method of identifying an antigen binding protein, comprising contacting a cell with an HLA-multimer comprising at least one HLA-PEPTIDE target listed in Table A; and identifying the antigen binding protein via binding between the HLA-multimer and the antigen binding protein.

174 . (canceled)

175 . The method of claim 173 , wherein the cell is a T cell.

176 - 178 . (canceled)

179 . A method of identifying an antigen binding protein, comprising obtaining the HLA-PEPTIDE target of claim 97 ; administering the HLA-PEPTIDE target to a subject, optionally in combination with an adjuvant; and isolating the antigen binding protein from the subject.

180 . A method of identifying an antigen binding protein, comprising contacting a cell with an HLA-multimer comprising the HLA-PEPTIDE target of claim 97 ; and identifying the antigen binding protein via binding between the HLA-multimer and the antigen binding protein.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE ERRONEOUS REFERENCE TO APPLICATION NUMBERS 10847252, 10847253 AND 11183286 TO INSTEAD REFLECT THE PATENT NUMBERS LISTED IN THE RECORDED ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED ON REEL 70760 FRAME 165. ASSIGNOR(S) HEREBY CONFIRMS THE THE ASSIGNMENT. Recorded Apr 25, 2025
From: GRITSTONE BIO, INC.
To: SEATTLE PROJECT CORP.
Reel/Frame 071079/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2025
From: GRITSTONE BIO, INC.
To: SEATTLE PROJECT CORP.
Reel/Frame 070760/0165 →
CHANGE OF NAME Recorded Dec 28, 2022
From: GRITSTONE ONCOLOGY, INC.
To: GRITSTONE BIO, INC.
Reel/Frame 062248/0904 →
CORRECTIVE ASSIGNMENT TO CORRECT THE FIFTH INVENTOR'S NAME PREVIOUSLY RECORDED AT REEL: 062085 FRAME: 0723. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Dec 23, 2022
From: JOOSS, KARIN; BLAIR, WADE; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER; BUSBY, MICHELE ANNE; FRANCIS, JOSHUA MICHAEL; GROTENBREG, GIJSBERT MARNIX; SKOBERNE, MOJCA; YELENSKY, ROMAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 062212/0233 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2022
From: JOOSS, KARIN; BLAIR, WADE; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER; BUSBY, MICHELLE ANNE; FRANCIS, JOSHUA MICHAEL; GROTENBREG, GIJSBERT MARNIX; SKOBERNE, MOJCA; YELENSKY, ROMAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 062085/0723 →